FFilingSight

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →

Regeneron Pharmaceuticals

REGNHealthcare

Generated Aug 19, 2026, 09:41 PM UTC

analytical score 3

REGN (Regeneron Pharmaceuticals) analytical snapshot. Revenue grew +1.0% YoY to $14.34B. 5-year revenue CAGR -2.3%; 10y CAGR +12.8%. Net margin at 31.41% (contracting ▼). Market cap $79.00B at $840.84 per share. Trailing P/E 20.27, P/S 5.51, P/B 2.49. EV/Operating income ≈ 21.95 (EV $78.53B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score 3 (data confidence 83%). Descriptive analytics from public filings — not investment advice.

Market cap
$79.00B
93.96M shares
Price
$840.84
NMS
P/E (ttm)
20.27
Revenue (FY)
$14.34B
YoY +1.0%
Net margin
31.41%
▼ 4.23pp
Free cash flow
$4.08B
28.45% margin
Risk level
Low

Free SEC analysis

— computed from SEC filings, free to read
Free previewRegulatory Analyst

Filings & Ownership

Regulatory Analyst
score 20Improving
80% conf

Latest annual report (10-K) filed Feb 4, 2026. Latest quarterly report (10-Q) filed Jul 30, 2026. 14 recent 8-K material-event filings in the index.

  • Latest annual report (10-K) filed Feb 4, 2026.
  • Latest quarterly report (10-Q) filed Jul 30, 2026.
  • 14 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference Regeneron Pharmaceuticals; broad institutional reporting.
  • Recent filers include BAKER BROS ADVISORS LLC, BAKER BROS ADVISORS LLC, CANYON CAPITAL ADVISORS LLC.
  • 20 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 4, 2026
Annual report
Latest 10-Q
Jul 30, 2026
8-K (recent)
14
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
FilerFormFiled
BAKER BROS ADVISORS LLC13F-HRSep 19, 2003
BAKER BROS ADVISORS LLC13F-HRSep 19, 2003
CANYON CAPITAL ADVISORS LLC13F-HRMay 15, 2003
CANYON CAPITAL ADVISORS LLC13F-HRAug 15, 2002
Invus Public Equities Advisors, LLC13F-HRNov 13, 2007
Recent 8-K material events
DateFormDescription
Jul 30, 20268-K8-K
Jul 6, 20268-KFORM 8-K
Jun 17, 20268-KFORM 8-K
Apr 29, 20268-K8-K
Apr 8, 20268-KFORM 8-K
Jan 30, 20268-K8-K
Jan 12, 20268-KFORM 8-K
Oct 28, 20258-K8-K
Sources:SEC EDGAR — Company FilingsSEC EDGAR — Full-Text Search
Free previewSEC Filing Analyst

SEC Filing Deep-Analysis

SEC Filing Analyst
score -15Deteriorating
70% conf

1 risk signal(s) detected from XBRL filing diff analysis. 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.

  • Restatement of financial statements: The term "restatement of" "previously issued" appears in 3 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
  • Endogenous analysis: 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
  • 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • Ongoing high-severity risk language: Restatement of financial statements.
Revenue
$14.34B
+1.0% YoY
Operating income
$3.58B
-10.3% YoY
Net income
$4.50B
+2.1% YoY
Operating cash flow
$4.98B
+12.6% YoY
Capex
$898.4M
+18.9% YoY
Total assets
$40.56B
+7.4% YoY
Total liabilities
$9.30B
+10.7% YoY
Long-term debt
$1.99B
+0.1% YoY
Filing quality score
72/100
1 new disclosures
SEC XBRL metric changes (latest annual vs prior)
MetricPrior yearLatest yearChange% Change
Revenue$14.20B$14.34B$140.9M+1.0%
Operating income$3.99B$3.58B$-412.8M-10.3%
Net income$4.41B$4.50B$92.3M+2.1%
Operating cash flow$4.42B$4.98B$558.4M+12.6%
Capex$755.9M$898.4M$142.5M+18.9%
Total assets$37.76B$40.56B$2.80B+7.4%
Total liabilities$8.41B$9.30B$896.0M+10.7%
Long-term debt$1.98B$1.99B$1.5M+0.1%
Cash & equivalents$2.49B$3.12B$629.9M+25.3%
Stockholders equity$29.35B$31.26B$1.90B+6.5%
Inventory$3.09B$3.20B$113.5M+3.7%
Accounts receivable$6.21B$5.74B$-470.8M-7.6%
R&D expense$5.13B$5.85B$718.2M+14.0%
SG&A expense$2.95B$2.70B$-254.4M-8.6%
Interest expense$59.4M$73.0M$13.6M+22.9%
XBRL disclosure changes (new vs dropped concepts)
TypeConcepts
AddedFinanceLeaseLiabilityCurrent
RemovedAccountsPayableAndAccruedLiabilitiesCurrent, AmortizationOfIntangibleAssets, BusinessCombinationContingentConsiderationLiability, CommonStockDividendsPerShareCashPaid, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger, DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
Risk language in filing text (EDGAR full-text search)
TermSeverityRecentPriorStatus
Restatement of financial statementshigh31Ongoing
Impairment chargemedium58Ongoing
Restructuringmedium58Ongoing
Off-balance sheet arrangementsmedium51Ongoing
Related party transactionslow10NEW
Filing signal breakdown
Red flags: 1
Positive: 0
Watch: 0
Red flags
Positive
Watch
Sources:SEC EDGAR — Company Facts (XBRL)SEC EDGAR — Financial Reports
Free previewFundamentals Analyst

Fundamentals

Fundamentals Analyst
score 5Stable
80% conf

Revenue grew +1.0% YoY to $14.34B. 5-year revenue CAGR -2.3%; 10y CAGR +12.8%. Net margin at 31.41% (contracting ▼).

  • Revenue grew +1.0% YoY to $14.34B.
  • 5-year revenue CAGR -2.3%; 10y CAGR +12.8%.
  • Net margin at 31.41% (contracting ▼).
  • Return on equity 14.41%, ROA 11.11%, ROIC 10.76%.
  • Gross margin 0.00%, operating margin 24.95%.
  • Free cash flow margin 28.45% ($4.08B).
  • Net income up ▲ +2.1% YoY.
  • Debt/equity 0.06, current ratio 3.34, net debt -$469.2M.
  • Asset turnover 0.34 — capital efficiency.
Revenue (FY)
$14.34B
YoY +1.0%
Net margin
31.41%
▼ 4.23pp
ROE
14.41%
ROA 11.11%
ROIC
10.76%
EPS (diluted)
$41.48
FY2025
Free cash flow
$4.08B
28.45% margin
Debt / equity
0.06
Cash $2.46B
Current ratio
3.34
Equity $31.71B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
FYRevenueRev YoYGross%Op%Net%FCFROE%
2024$14.20B+8.3%0.0028.1031.07$3.66B15.03
2025$14.34B+1.0%0.0024.9531.41$4.08B14.41
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
Quarter endRevenueYoYQoQNet margin
Jun 30, 2016$1.21B+21.4%—16.18%
Sep 30, 2016$1.22B+7.3%+0.6%21.70%
Mar 31, 2017$1.32B+9.8%+8.1%18.87%
Jun 30, 2017$1.47B+21.2%+11.5%26.38%
Sep 30, 2017$1.50B+23.0%+2.1%25.88%
Mar 31, 2018$1.51B+14.6%+0.7%31.62%
Sources:SEC EDGAR — Company Facts (XBRL)
+8 more years of history, charts & full breakdown Pro

Pro analysis — preview

— score, signals & key metrics shown; full reasoning locked

Valuation

Valuation Analyst
score -30Deteriorating
95% conf

Market cap $79.00B at $840.84 per share. Trailing P/E 20.27, P/S 5.51, P/B 2.49. EV/Operating income ≈ 21.95 (EV $78.53B).

  • Market cap $79.00B at $840.84 per share.
Market cap
$79.00B
93.96M shares
P/E (ttm)
20.27
P/S
5.51
P/B
2.49
EV
$78.53B
Intrinsic (DCF)
$747.11
-11.1% vs price
ProFull breakdown & reasoning locked

Price & Technicals

Technical Analyst
score 50Improving
85% conf

Price $840.84 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 92.15 (overbought).

  • Price $840.84 — uptrend (above 200-DMA); 1-month momentum positive.
Price
$840.84
NMS
RSI(14)
92.15
50-DMA
$683.14
200-DMA
$721.98
Volatility (ann.)
33.50%
52w range
$541.00–$844.90
-0.5% from high
ProFull breakdown & reasoning locked

Macro & Rates

Macro Analyst
score 30Improving
80% conf

Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.

  • Market regime: Risk-on · Supportive.
GDP growth
1.50%
CPI (YoY)
+3.3%
Fed funds
3.63%
10Y yield
4.71%
10Y−2Y
0.46pp
Unemployment
4.10%
ProFull breakdown & reasoning locked

Risk Scorecard

Risk Analyst
score 10Stable
90% conf

Composite risk Low. Leverage debt/equity 0.06 (low). Liquidity current ratio 3.34 (adequate).

  • Composite risk: Low.
Risk level
Low
Debt / equity
0.06
Current ratio
3.34
Margin stdev
29.02pp
Cash / assets
5.88%
Liab / assets
24.01%
ProFull breakdown & reasoning locked

See the full picture behind every stock

Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.

Subscribe to ProCreate free account

3 sections free · 4 Pro previews · composite 3

Macro exposure

Defensive · Low sensitivity
Neutral

Macro regime: Risk-on · Supportive. Regeneron Pharmaceuticals is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.

Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
15.84
Fed funds
3.63%
CPI YoY
+3.3%

Analytical read

deterministic preview

Price $840.84 — uptrend (above 200-DMA); 1-month momentum positive..

Risk
Low
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Open analytical workspace

Peer comparison

Defensive group

How REGN stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.

CompanyScoreMacro
DexCom Inc. DXCM21Neutral
Bristol-Myers Squibb BMY19Neutral
Eli Lilly & Co. LLY17Neutral
Gilead Sciences GILD10Neutral
HCA Healthcare HCA9Neutral
Johnson & Johnson JNJ8Neutral
Abbott Laboratories ABT7Neutral
Biogen Inc. BIIB7Neutral
Intuitive Surgical Inc. ISRG7Neutral
Coca-Cola Co. KO6Neutral
Thermo Fisher Scientific TMO3Neutral
Regeneron Pharmaceuticals REGN● you3Neutral
Danaher Corp. DHR1Neutral
Merck & Co. MRK0Neutral
Zoetis Inc. ZTS0Neutral
Illumina Inc. ILMN0Neutral
Vertex Pharmaceuticals VRTX0Neutral
Colgate-Palmolive CL-2Neutral
AbbVie Inc. ABBV-5Neutral
Procter & Gamble PG-7Neutral
CVS Health Corp. CVS-8Neutral
Mondelez International MDLZ-10Neutral
Amgen Inc. AMGN-10Neutral
Cigna Group CI-11Neutral
Kroger Co. KR-13Neutral
Costco Wholesale COST-14Neutral
Walmart Inc. WMT-14Neutral
Pfizer Inc. PFE-15Neutral
PepsiCo Inc. PEP-16Neutral
Sysco Corp. SYY-16Neutral
Hershey Co. HSY-17Neutral
Kimberly-Clark Corp. KMB-18Neutral
Moderna Inc. MRNA-21Neutral
UnitedHealth Group UNH-25Neutral